Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer

Apricus Biosciences Appoints Richard W. Pascoe as Chief Executive Officer

Steve Martin to Resume Role as Chief Financial Officer

SAN DIEGO, March 18, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) today
announced the appointment of Richard W. Pascoe as Chief Executive Officer of
the Company, effective March 18, 2013. Mr. Pascoe brings to Apricus Bio over
20 years of experience in corporate strategy as well as product development,
sales and marketing in the biopharmaceutical industry, and has held positions
of increasing responsibility at leading, innovative life science companies,
including Somaxon Pharmaceuticals, ARIAD Pharmaceuticals and King
Pharmaceuticals. In addition to his role as CEO, he has also joined the
Company's Board of Directors.With Mr. Pascoe's appointment, Steve Martin,
Interim Chief Executive Officer, will resume his responsibilities as Senior
Vice President and Chief Financial Officer.

"Richard has a proven record of setting and executing on value-building
corporate strategy.His experience covers international strategic partnerships
as well as product development, commercialization, sales and marketing," said
Rusty Ray, Chairman of the Board."This background will be key to the
successful execution of Apricus Bio's strategy as we enter a transformative
period for the Company.We look forward to Richard's insights and direction at
this pivotal time, as we advance the development and commercialization of
Vitaros® and Femprox® in markets around the world."

Mr. Pascoe commented, "Apricus Bio has set itself apart as an innovator in
male and female sexual health, addressing markets with significant commercial
potential that are vastly underserved by products currently marketed in those
indications. I am eager to join the team and build upon the significant
progress made to date in developing and commercializing these novel products
in markets around the world."

Mr. Pascoe joins Apricus Bio from Somaxon Pharmaceuticals, Inc., where he was
Chief Executive Officer since August 2008.At Somaxon, Mr. Pascoe was
responsible for the FDA approval and successful commercialization of the
Company's lead drug Silenor^® and its recent sale to Pernix Therapeutics.
Prior to Somaxon, Mr. Pascoe was with ARIAD Pharmaceuticals, Inc., a specialty
pharmaceutical company engaged in the discovery and development of oncology
product candidates, where he was most recently Senior Vice President and Chief
Operating Officer. In that role, and in his previous role as ARIAD's Chief
Commercial Officer, Mr. Pascoe played a key role in developing and managing
the implementation of ARIAD's corporate strategies.

Prior to joining ARIAD in 2005, Mr. Pascoe held a series of senior management
roles at King Pharmaceuticals, Inc., a specialty pharmaceutical company,
including Senior Vice President positions in both marketing and sales, as well
as Vice President positions in both international sales and marketing and
hospital sales. Prior to King, Mr. Pascoe was in the commercial groups at
Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc., B.
Braun Interventional and The BOC Group. Mr. Pascoe served as a Commissioned
Officer with the U.S. Army 24th Infantry Division, including as an advisor to
the Brigade Commander during Operation Desert Storm. Mr. Pascoe received his
B.S. degree in Leadership Studies from the United States Military Academy at
West Point.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that
develops and markets innovative treatments that help large patient populations
across numerous, large-market therapeutic classes including male and female
sexual health. The Company has one approved product, Vitaros®, for the
treatment of erectile dysfunction, which will be marketed in Canada by Abbott
Laboratories, and Femprox®, a product candidate, for the treatment of female
sexual arousal disorder, which successfully completed one 400-patient Phase
III study in China.

For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to: its ability to achieve its
development, commercialization and financial goals, its ability to further
develop its products and product candidates, the timing for the commercial
launch of Vitaros^® in Canada, and its ability to have its products including
Vitaros® and product candidates including Femprox® approved by relevant
regulatory authorities, including in various countries around the world.
Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking
statements contained herein. Readers are urged to read the risk factors set
forth in the Company's most recent annual report on Form 10-K, subsequent
quarterly reports filed on Form 10-Q and other filings made with the SEC.
Copies of these reports are available from the SEC's website or without charge
from the Company.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
 
Press spacebar to pause and continue. Press esc to stop.